Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013

Affiliations

¹ Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.
² Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK. Electronic address: johann.de-bono@icr.ac.uk.

Comment

Niven Mehra et al. Eur Urol. 2018 Sep.

. 2018 Sep;74(3):e69-e70.

doi: 10.1016/j.eururo.2018.05.016. Epub 2018 Jun 1.

¹ Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.
² Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK. Electronic address: johann.de-bono@icr.ac.uk.

No abstract available

Comment on

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Macé S, de Bono JS. Mehra N, et al. Eur Urol. 2018 Sep;74(3):283-291. doi: 10.1016/j.eururo.2018.02.013. Epub 2018 Feb 28. Eur Urol. 2018. PMID: 29500065 Free PMC article. Clinical Trial.
Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol 2018;74:283-91.
Conteduca V, Gurioli G, De Giorgi U. Conteduca V, et al. Eur Urol. 2018 Sep;74(3):e67-e68. doi: 10.1016/j.eururo.2018.05.015. Epub 2018 May 24. Eur Urol. 2018. PMID: 29803584 No abstract available.